LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects
International Journal of Molecular Sciences · 07.03.2023 · 24 (6) · 5082
DOI: 10.3390/ijms24065082 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.03.2023. Verfasst von Felix Duprat und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Lipoproteins and Cancer, Pathophysiology Department, Universidad de Concepción, Concepción 4030000, Chile. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondecyt, ANID, FONDECYT.
Abstract (Originalsprache)
The oxidized low-density lipoprotein receptor 1 (LOX-1) is one of the most important receptors for modified LDLs, such as oxidated (oxLDL) and acetylated (acLDL) low-density lipoprotein. LOX-1 and oxLDL are fundamental in atherosclerosis, where oxLDL/LOX1 promotes ROS generation and NF-κB activation inducing the expression of IL-6, a STAT3 activator. Furthermore, LOX-1/oxLDL function has been associated with other diseases, such as obesity, hypertension, and cancer. In prostate cancer (CaP), LOX-1 overexpression is associated with advanced stages, and its activation by oxLDL induces an epithelial-mesenchymal transition, increasing angiogenesis and proliferation. Interestingly, enzalutamide-resistant CaP cells increase the uptake of acLDL. Enzalutamide is an androgen receptor (AR) antagonist for castration-resistant prostate cancer (CRPC) treatment, and a high percentage of patients develop a resistance to this drug. The decreased cytotoxicity is promoted in part by STAT3 and NF-κB activation that induces the secretion of the pro-inflammatory program and the expression of AR and its splicing variant AR-V7. Here, we demonstrate for the first time that oxLDL/LOX-1 increases ROS levels and activates NF-κB, inducing IL-6 secretion and the activation of STAT3 in CRPC cells. Furthermore, oxLDL/LOX1 increases AR and AR-V7 expression and decreases enzalutamide cytotoxicity in CRPC. Thus, our investigation suggests that new factors associated with cardiovascular pathologies, such as LOX-1/oxLDL, may also promote important signaling axes for the progression of CRPC and its resistance to drugs used for its treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Lipoproteins and Cancer, Pathophysiology Department, Universidad de Concepción, Concepción 4030000, Chile.
- Pharmacology Department, Universidad de Concepción, Concepción 4030000, Chile.
- Centro de Microscopía Avanzada, CMA-BIO BIO, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.
- Biotechnology and Biopharmaceuticals Laboratory, Pathophysiology Department, Universidad de Concepción, Concepción 4030000, Chile.
- Laboratory of Natural Products & Drug Discovery, Center CEBIM, Department of Basic Sciences, Universidad de La Frontera, Temuco 4780000, Chile.
ORCID-Profile: Romina Bertinat, Cristian Paz, Iván González-Chavarría
Förderung
- Fondecyt
- ANID, FONDECYT
Zitieren
APA
Duprat, F., Robles, C., Castillo, M. P., Rivas, Y., Mondaca, M., Jara, N., Roa, F., Bertinat, R., Toledo, J., Paz, C., & González-Chavarría, I. (2023). LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects. International Journal of Molecular Sciences, 24(6), 5082. https://doi.org/10.3390/ijms24065082
Vancouver
Duprat F, Robles C, Castillo MP, Rivas Y, Mondaca M, Jara N, et al. LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects. International Journal of Molecular Sciences. 2023;24(6):5082. doi:10.3390/ijms24065082
BibTeX
@article{Duprat2023,
author = {Duprat, Felix and Robles, Catalina and Castillo, María Paz and Rivas, Yerko and Mondaca, Marcela and Jara, Nery and Roa, Francisco and Bertinat, Romina and Toledo, Jorge and Paz, Cristian and González-Chavarría, Iván},
title = {LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5082},
doi = {10.3390/ijms24065082}
}
EUVIMED